Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models

Reuters

10/24

Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models

Immunome Inc. announced the presentation of preclinical data for its proprietary antibody-drug conjugate $(ADC)$ payload HC74 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston on October 23, 2025. The data demonstrate that HC74, a novel topoisomerase I inhibitor, overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is used as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, as well as in several preclinical candidates in Immunome's pipeline. The results showed that HC74 retains efficacy in tumor models with over-expression of drug efflux transporters and in models of colorectal cancer and non-small cell lung cancer resistant to existing therapies. The full poster is available on Immunome's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023619001) on October 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577098589"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577098589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577098589?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577098589","market":"us","top_or_hot":-1,"title":"Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMNM\">Immunome Inc.</a> announced the presentation of preclinical data for its proprietary antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> payload HC74 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, held in Boston on October 23, 2025. The data demonstrate that HC74, a novel topoisomerase I inhibitor, overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is used as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, as well as in several preclinical candidates in Immunome's pipeline. The results showed that HC74 retains efficacy in tumor models with over-expression of drug efflux transporters and in models of colorectal cancer and non-small cell lung cancer resistant to existing therapies. The full poster is available on Immunome's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023619001) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMNM\">Immunome Inc.</a> announced the presentation of preclinical data for its proprietary antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> payload HC74 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, held in Boston on October 23, 2025. The data demonstrate that HC74, a novel topoisomerase I inhibitor, overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is used as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, as well as in several preclinical candidates in Immunome's pipeline. The results showed that HC74 retains efficacy in tumor models with over-expression of drug efflux transporters and in models of colorectal cancer and non-small cell lung cancer resistant to existing therapies. The full poster is available on Immunome's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023619001) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL6mbvTP:1","article_id":"2577098589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577098589","pubTimestamp":1761235224,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunome Inc. announced the presentation of preclinical data for its proprietary antibody-drug conjugate  payload HC74 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston on October 23, 2025. The data demonstrate that HC74, a novel topoisomerase I inhibitor, overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is used as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, as well as in several preclinical candidates in Immunome's pipeline. The results showed that HC74 retains efficacy in tumor models with over-expression of drug efflux transporters and in models of colorectal cancer and non-small cell lung cancer resistant to existing therapies. The full poster is available on Immunome's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","IMNM":"Immunome Inc.","BK4139":"生物科技"},"translate_title":"Immunome公布临床前数据显示HC74 ADC有效负载克服癌症模型中的耐药性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNM":0.9},"content_text":"Immunome Unveils Preclinical Data Showing HC74 ADC Payload Overcomes Drug Resistance in Cancer Models\n    \n\nImmunome Inc. announced the presentation of preclinical data for its proprietary antibody-drug conjugate $(ADC)$ payload HC74 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston on October 23, 2025. The data demonstrate that HC74, a novel topoisomerase I inhibitor, overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is used as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, as well as in several preclinical candidates in Immunome's pipeline. The results showed that HC74 retains efficacy in tumor models with over-expression of drug efflux transporters and in models of colorectal cancer and non-small cell lung cancer resistant to existing therapies. The full poster is available on Immunome's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023619001) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}